NeurologyLive Friday 5 — January 22, 2021

January 22, 2021
NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Economic Burden for SMA Management Continues to Rise

The average number of inpatient claims per year was higher for patients with SMA than their matched non-SMA patients, with respiratory illness the most common reason for an inpatient admission among all patients with SMA.

2: NeuroVoices: Christian Agudelo, MD, on Sleep’s Impact on Cognitive Decline

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

3: Richard B. Lipton, MD: Achieving Simultaneous Acute and Preventive Migraine Treatment

The director of the Montefiore Headache Center discussed how his team’s recent study findings could change the way physicians think about treating migraine.

4: Safety and Efficacy of CBD in Patients With TSC

Trevor Resnick, MD, examines the 4-year results from the expanded access program of the long-term safety and efficacy of cannabidiol (CBD) in patients with tuberous sclerosis complex (TSC).

5: FDA Clears First Rapid Traumatic Brain Injury Blood Test

Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.